SCHEMBL17870960

SCHEMBL17870960

CC(C)S(=O)(=O)N1C(=O)C[C@H]1c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.42
ATM Q13315 1/20 0.42
RIPK1 Q13546 4/20 0.41
BRD4 O60885 3/20 0.39
KMT2A Q03164 2/20 0.39
RAB9A P51151 1/20 0.39
TSHR P16473 1/20 0.39
PKM P14618 1/20 0.38
CHRNB2 P17787 1/20 0.38
CHRNB4 P30926 1/20 0.38
CHRNA3 P32297 1/20 0.38
CHRNA7 P36544 1/20 0.38
CHRNA4 P43681 1/20 0.38
GRIA4 P48058 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19471147 1.00 ALDH1A1 (0.42) ALDH1A1ATMRIPK1BRD4KMT2A
SCHEMBL17870936 0.79 RIPK1 (0.49) ALDH1A1ATMRIPK1BRD4KMT2A
SCHEMBL19471191 0.79 RIPK1 (0.49) ALDH1A1ATMRIPK1BRD4KMT2A
SCHEMBL17870950 0.77 RIPK1 (0.48) ALDH1A1ATMRIPK1BRD4KMT2A
SCHEMBL19471106 0.77 RIPK1 (0.48) ALDH1A1ATMRIPK1BRD4KMT2A
SCHEMBL1827356 0.73 RIPK1 (0.45) ALDH1A1ATMRIPK1BRD4KMT2A
SCHEMBL8119921 0.69 KMT2A (0.47) ALDH1A1ATMRIPK1BRD4KMT2A
SCHEMBL31462385 0.69 RIPK1 (0.38) ALDH1A1ATMRIPK1KMT2ARAB9A
SCHEMBL11970774 0.66 ALDH1A1 (0.59) ALDH1A1ATMBRD4KMT2ATSHR
SCHEMBL22929174 0.66 RIPK1 (0.45) ALDH1A1ATMRIPK1BRD4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11478438-B2 Necrosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2022-10-25 US disclosed
US-11090307-B2 Treating male senescence NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2021-08-17 US disclosed
CN-107108492-B Cell necrosis inhibitor 北京生命科学研究所 2021-03-19 CN disclosed
US-20200182617-A1 Necrosis Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2020-06-11 US disclosed
US-20200182617-A1 Necrosis Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2020-06-11 US disclosed
US-20200046714-A1 Treating Male Senescence NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2020-02-13 US disclosed
US-10555920-B2 Necrosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2020-02-11 US disclosed
US-10555920-B2 Necrosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2020-02-11 US disclosed
US-20190038578-A1 Necrosis Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2019-02-07 US disclosed
US-20190038578-A1 Necrosis Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2019-02-07 US disclosed
US-10092529-B2 Necrosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2018-10-09 US disclosed
EP-3224245-B1 NECROSIS INHIBITORS NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) 2018-09-12 EP disclosed
US-20170304237-A1 Necrosis Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2017-10-26 US disclosed
US-20170304237-A1 Necrosis Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2017-10-26 US disclosed
US-20170304237-A1 Necrosis Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2017-10-26 US disclosed
EP-3224245-A1 NECROSIS INHIBITORS National Institute Of Biological Sciences, Beijing (CN) 2017-10-04 EP disclosed
WO-2016101887-A1 NECROSIS INHIBITORS NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2016-06-30 WO disclosed
WO-2016101887-A1 NECROSIS INHIBITORS NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2016-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170304237-A1 Necrosis Inhibitors RIPK3, RIPK1, RIPK4 ALDH1A1 3900/4885ATM 2591/4885RIPK1 2/4885
US-11478438-B2 Necrosis inhibitors RIPK3, RIPK1, RIPK4 ALDH1A1 4104/4885ATM 2498/4885RIPK1 2/4885
US-11090307-B2 Treating male senescence RIPK3, RIPK1, MLKL ALDH1A1 2786/4885ATM 401/4885RIPK1 2/4885
US-20200046714-A1 Treating Male Senescence RIPK3, RIPK1, MLKL ALDH1A1 2786/4885ATM 401/4885RIPK1 2/4885
US-20190038578-A1 Necrosis Inhibitors RIPK3, RIPK1, RIPK4 ALDH1A1 4104/4885ATM 2498/4885RIPK1 2/4885
US-10092529-B2 Necrosis inhibitors RIPK3, RIPK1, RIPK4 ALDH1A1 3900/4885ATM 2591/4885RIPK1 2/4885
US-10555920-B2 Necrosis inhibitors RIPK3, RIPK1, RIPK4 ALDH1A1 4104/4885ATM 2498/4885RIPK1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.